Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Countries such as South Africa have limited intensive care unit (ICU) capacity to handle the expected number of patients with COVID-19 requiring ICU care. Remdesivir can prevent deaths in countries such as South Africa by decreasing the number of days people spend in ICU, therefore freeing up ICU bed capacity.

Original publication

DOI

10.1093/cid/ciaa937

Type

Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Publication Date

05/2021

Volume

72

Pages

1642 - 1644

Addresses

Department of Global Health, School of Public Health, Boston University, Boston, Massachusetts, USA.

Keywords

Humans, Alanine, Adenosine Monophosphate, Intensive Care Units, South Africa, COVID-19, SARS-CoV-2